SI3189830T1 - Formulacija zdravila z zakasnjenim sproščanjem - Google Patents

Formulacija zdravila z zakasnjenim sproščanjem Download PDF

Info

Publication number
SI3189830T1
SI3189830T1 SI201331070T SI201331070T SI3189830T1 SI 3189830 T1 SI3189830 T1 SI 3189830T1 SI 201331070 T SI201331070 T SI 201331070T SI 201331070 T SI201331070 T SI 201331070T SI 3189830 T1 SI3189830 T1 SI 3189830T1
Authority
SI
Slovenia
Prior art keywords
formulation
polymeric material
delayed release
core
coating
Prior art date
Application number
SI201331070T
Other languages
English (en)
Inventor
Gonzalez Roberto Carlos Bravo
Thomas Buser
Frederic Jean-Claude Goutte
Abdul Waseh Basit
Felipe Jose Oliveria Varum
Ana Cristina Freire
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3189830(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of SI3189830T1 publication Critical patent/SI3189830T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Grain Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

  1. FORMULACIJA ZDRAVILA Z ZAKASNJENIM SPROŠČANJEM Patentni zahtevki
    1. Formulacija zdravila z zakasnjenim sproščanjem za peroralno dajanje za dovajanje zdravila v kolon osebka, pri čemer formulacija obsega: jedro in oblogo za jedro, pri čemer jedro obsega zdravilo in obloga obsega zunanji sloj in notranji sloj, pri čemer zunanji sloj obsega zmes prvega polimernega materiala, ki je dovzeten za napade bakterij v kolonu, in drugega polimernega materiala, ki ima mejo pH pri pH 6 ali višje in pri čemer notranji sloj obsega tretji polimerni material, ki je neionski polimer, ki je topen v črevesni tekočini ali gastrointestinalni tekočini, in vsaj en aditiv, izbran izmed pufrskega sredstva in baze.
  2. 2. Formulacija zdravila z zakasnjenim sproščanjem po zahtevku 1, pri čemer je neionski polimer izbran izmed metilceluloze (MC); hidroksipropilceluloze (HPC); hidroksipropilmetilceluloze (HPMC); poli(etilenoksid)-graft-polivinilalkohola; polivinilpirolidona (PVP); polietilen glikola (PEG); in polivinilalkohola (PVA).
  3. 3. Formulacija zdravila z zakasnjenim sproščanjem po zahtevku 1 ali zahtevku 2, pri čemer notranji sloj obsega vsaj eno pufrsko sredstvo in vsaj eno bazo.
  4. 4. Formulacija zdravila z zakasnjenim sproščanjem po katerem koli od predhodnih zahtevkov, pri čemer je pufer fosfatna sol.
  5. 5. Formulacija zdravila z zakasnjenim sproščanjem po katerem koli od predhodnih zahtevkov, pri čemer je pufer kalijev dihidrogenfosfat.
  6. 6. Formulacija zdravila z zakasnjenim sproščanjem po katerem koli od predhodnih zahtevkov, pri čemer je pufer prisoten v notranjem sloju v količini od 0,1 mas. % do 20 mas. % na osnovi suhe mase tretjega polimernega materiala.
  7. 7. Formulacija zdravila z zakasnjenim sproščanjem po katerem koli od predhodnih zahtevkov, pri čemer je baza hidroksidna baza.
  8. 8. Formulacija zdravila z zakasnjenim sproščanjem po katerem koli od predhodnih zahtevkov, pri čemer je baza natrijev hidroksid.
  9. 9. Formulacija zdravila z zakasnjenim sproščanjem po katerem koli od predhodnih zahtevkov, pri čemer je drugi polimerni material mešanica vsaj dveh polimerov, ki imata mejo pH pri pH 6 ali višje.
  10. 10. Formulacija zdravila z zakasnjenim sproščanjem po katerem koli od predhodnih zahtevkov, pri čemer sta prvi in drugi polimerni material prisotna v zunanjem sloju v razmerju do 60 : 40.
  11. 11. Postopek izdelave formulacije zdravila z zakasnjenim sproščanjem za peroralno dajanje za dovajanje zdravila v kolon osebka po zahtevku 1, pri čemer postopek obsega: tvorjenje jedra, ki obsega zdravilo; oblaganje jedra z uporabo pripravka za notranjo oblogo, ki obsega tretji polimerni material, ki je topen v črevesni tekočini ali gastrointestinalni tekočini, v sistemu topil, da se tvori notranje obloženo jedro, in; oblaganje notranjega obloženega jedra s pripravkom za zunanjo oblogo, ki obsega prvi polimerni material, ki je dovzeten za napad bakterij v kolonu, in drugi polimerni material, ki ima mejo pH pri pH 6 ali višje, v sistemu topil, da se tvori zunanje obloženo jedro, pri čemer je tretji polimerni material neionski polimer in pripravek za notranjo oblogo obsega vsaj en aditiv, izbran izmed pufrskega sredstva in baze.
  12. 12. Postopek po zahtevku 11, pri čemer je sistem topil pripravka za notranjo oblogo vodni.
  13. 13. Postopek po zahtevku 11, pri čemer je tretji polimerni material neionski polimer, pH pripravka za notranjo oblogo je naravnan pred oblaganjem na vsaj 0,5 pH-enote višje od meje pH drugega polimernega materiala.
  14. 14. Postopek po zahtevkih od 11 do 13, pri čemer je pH pripravka za notranjo oblogo naravnan tako, da je od pH 7,5 do pH 10, prednostno od pH 7,5 do pH 8,5, bolj prednostno okoli pH 8.
  15. 15. Postopek po katerem koli od zahtevkov od 11 do 14, pri čemer je baza hidroksid.
SI201331070T 2012-04-30 2013-04-29 Formulacija zdravila z zakasnjenim sproščanjem SI3189830T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261640217P 2012-04-30 2012-04-30
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation
EP17156227.5A EP3189830B1 (en) 2012-04-30 2013-04-29 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
SI3189830T1 true SI3189830T1 (sl) 2018-08-31

Family

ID=46025554

Family Applications (5)

Application Number Title Priority Date Filing Date
SI201231190T SI2659881T1 (sl) 2012-04-30 2012-04-30 Formulacija zdravila z zakasnjenim sproščanjem
SI201331070T SI3189830T1 (sl) 2012-04-30 2013-04-29 Formulacija zdravila z zakasnjenim sproščanjem
SI201331380T SI2844220T1 (sl) 2012-04-30 2013-04-29 Formulacija zdravila z zakasnjenim sproščanjem
SI201331640T SI2844222T1 (sl) 2012-04-30 2013-04-29 Formulacija zdravila z zakasnjenim sproščanjem
SI201331409T SI3278792T1 (sl) 2012-04-30 2013-04-29 Formulacija zdravila z zakasnjenim sproščanjem

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201231190T SI2659881T1 (sl) 2012-04-30 2012-04-30 Formulacija zdravila z zakasnjenim sproščanjem

Family Applications After (3)

Application Number Title Priority Date Filing Date
SI201331380T SI2844220T1 (sl) 2012-04-30 2013-04-29 Formulacija zdravila z zakasnjenim sproščanjem
SI201331640T SI2844222T1 (sl) 2012-04-30 2013-04-29 Formulacija zdravila z zakasnjenim sproščanjem
SI201331409T SI3278792T1 (sl) 2012-04-30 2013-04-29 Formulacija zdravila z zakasnjenim sproščanjem

Country Status (40)

Country Link
US (6) US10226430B2 (sl)
EP (6) EP3187171A1 (sl)
JP (2) JP6621661B2 (sl)
KR (6) KR102177773B1 (sl)
CN (5) CN104271113B (sl)
AR (1) AR090898A1 (sl)
AU (4) AU2013255913B2 (sl)
BR (3) BR122019022551B1 (sl)
CA (4) CA2871016C (sl)
CL (2) CL2014002795A1 (sl)
CO (2) CO7141433A2 (sl)
CR (4) CR20190245A (sl)
CU (1) CU24304B1 (sl)
CY (4) CY1120215T1 (sl)
DK (5) DK2659881T3 (sl)
EA (2) EA032514B1 (sl)
ES (5) ES2655622T3 (sl)
GE (4) GEP201706753B (sl)
HR (2) HRP20180068T1 (sl)
HU (5) HUE036187T2 (sl)
JO (6) JOP20200144A1 (sl)
LT (5) LT2659881T (sl)
ME (2) ME03641B (sl)
MX (3) MX366677B (sl)
MY (3) MY169161A (sl)
NO (1) NO2659881T3 (sl)
NZ (3) NZ629260A (sl)
PE (3) PE20190625A1 (sl)
PH (2) PH12014502340B1 (sl)
PL (5) PL2659881T3 (sl)
PT (5) PT2659881T (sl)
RS (5) RS56839B1 (sl)
SA (2) SA113340508B1 (sl)
SG (2) SG11201406799XA (sl)
SI (5) SI2659881T1 (sl)
TN (2) TN2014000442A1 (sl)
TR (3) TR201905226T4 (sl)
TW (3) TWI700102B (sl)
UY (1) UY34772A (sl)
WO (2) WO2013164316A1 (sl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24342B1 (es) * 2012-04-30 2018-05-08 Tillotts Pharma Ag Formulación de fármaco de liberación retardada
HUE036187T2 (hu) 2012-04-30 2018-06-28 Tillotts Pharma Ag Késleltetett leadású gyógyszerkészítmény
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
ES2821766T3 (es) * 2013-02-22 2021-04-27 Zeria Pharm Co Ltd Comprimido con recubrimiento entérico
UA117260C2 (uk) 2013-10-29 2018-07-10 Тиллоттс Фарма АГ Лікарський препарат з відстроченим вивільненням
US10517869B2 (en) 2013-12-24 2019-12-31 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
US10945974B2 (en) 2015-06-01 2021-03-16 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
EP4119539A1 (en) 2015-09-23 2023-01-18 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
US11311573B2 (en) * 2016-11-30 2022-04-26 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
CA3094173A1 (en) * 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EA202092275A1 (ru) * 2018-03-23 2021-02-09 Палатин Текнолоджиз, Инк. Составы пептидов, специфичных к рецептору меланокортина, и способы доставки в желудочно-кишечный тракт
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3662902A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
EP3662898A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3666262B1 (en) * 2018-12-10 2021-11-10 Aphaia IP AG Pharmaceutical oral dosage forms for treatment of metabolic disorders and related diseases through orchestrated release of enterokines
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
EP4013401A4 (en) * 2019-08-12 2023-07-12 Massachusetts Institute of Technology ARTICLES AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS
CN115461046A (zh) * 2019-11-13 2022-12-09 爱的发制药集团 用于生产具有结肠递送的口服施用药物组合物的方法
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
CA2148465C (en) * 1992-11-06 1999-11-02 Minenobu Okayama Oral pharmaceutical preparation releasable in the lower digestive tract
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ATE238797T1 (de) * 1999-12-16 2003-05-15 Medinfar Produtos Farmaceutico Piroxicam enthaltende gastrointestinale zubereitung aus merheren einheiten bestehend
DE10013029A1 (de) * 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780A (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
WO2002096405A1 (fr) 2001-05-25 2002-12-05 Ssp Co., Ltd. Preparations de medicaments
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
AU2003304203A1 (en) * 2002-10-29 2005-01-04 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
CA2558535A1 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
JP2008543929A (ja) 2005-06-20 2008-12-04 カディラ・ヘルスケア・リミテッド デュロキセチンの調節放出型の投与製剤
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
WO2008020286A2 (en) 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
EP2079448A2 (en) * 2006-10-10 2009-07-22 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
US20100179170A1 (en) * 2006-12-05 2010-07-15 Lisa Claire Du Toit Heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
CA2684655A1 (en) * 2007-03-26 2008-10-02 Teikoku Seiyaku Co., Ltd. Oral pharmaceutical preparation for colon-specific delivery
US9597293B2 (en) * 2007-05-07 2017-03-21 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
MY172372A (en) 2009-06-15 2019-11-21 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
WO2011049309A2 (ko) * 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
US20130259947A1 (en) 2010-11-29 2013-10-03 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
US10799460B2 (en) 2011-09-07 2020-10-13 Roland SAUR-BROSCH Formulation for the controlled release of one or several substances in the digestive tract of a mammal
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
HUE036187T2 (hu) 2012-04-30 2018-06-28 Tillotts Pharma Ag Késleltetett leadású gyógyszerkészítmény
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
UA117260C2 (uk) 2013-10-29 2018-07-10 Тиллоттс Фарма АГ Лікарський препарат з відстроченим вивільненням

Also Published As

Publication number Publication date
TR201903569T4 (tr) 2019-04-22
KR102177773B1 (ko) 2020-11-12
EA201491783A1 (ru) 2014-12-30
US9364440B2 (en) 2016-06-14
RS56839B1 (sr) 2018-04-30
AU2017210577A1 (en) 2017-08-24
TW202037370A (zh) 2020-10-16
CN110237056A (zh) 2019-09-17
JP2015515964A (ja) 2015-06-04
DK2659881T3 (en) 2018-02-05
CN110200949B (zh) 2021-11-16
EP2844220A1 (en) 2015-03-11
PL3278792T3 (pl) 2019-09-30
MX366677B (es) 2019-07-19
NZ629262A (en) 2017-01-27
CN104271113A (zh) 2015-01-07
CL2014002795A1 (es) 2015-02-13
LT3189830T (lt) 2018-07-10
LT3278792T (lt) 2019-05-10
ES2655622T3 (es) 2018-02-20
JP6621661B2 (ja) 2019-12-18
NZ725409A (en) 2018-05-25
ES2761341T3 (es) 2020-05-19
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
ES2720258T3 (es) 2019-07-19
BR112014026935A2 (pt) 2017-06-27
MY190392A (en) 2022-04-20
HUE046628T2 (hu) 2020-03-30
TWI700102B (zh) 2020-08-01
PH12014502339B1 (en) 2014-12-22
CY1120215T1 (el) 2018-12-12
TWI618547B (zh) 2018-03-21
UY34772A (es) 2013-11-29
CR20190246A (es) 2019-09-03
MX362529B (es) 2019-01-23
PH12014502340A1 (en) 2014-12-22
DK3278792T3 (da) 2019-05-06
CN110237056B (zh) 2022-03-08
ME03641B (me) 2020-07-20
JOP20200147B1 (ar) 2023-09-17
US20170266117A1 (en) 2017-09-21
JOP20200146B1 (ar) 2023-09-17
EP3278792B1 (en) 2019-02-20
AU2013255913B2 (en) 2017-08-31
LT2844220T (lt) 2019-04-10
EP2844222B1 (en) 2019-11-13
KR20150004911A (ko) 2015-01-13
US11517534B2 (en) 2022-12-06
PL2844222T3 (pl) 2020-03-31
NZ629260A (en) 2017-01-27
HUE043238T2 (hu) 2019-08-28
JOP20200145A1 (ar) 2022-10-30
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (sl) 2018-03-30
EP2844222A1 (en) 2015-03-11
US20140056980A1 (en) 2014-02-27
EA032514B1 (ru) 2019-06-28
CR20140485A (es) 2015-01-19
PH12014502339A1 (en) 2014-12-22
KR20190127986A (ko) 2019-11-13
TW201720430A (zh) 2017-06-16
WO2013164316A1 (en) 2013-11-07
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
NO2659881T3 (sl) 2018-04-28
CL2014002796A1 (es) 2015-02-06
PE20150129A1 (es) 2015-02-13
SI2844220T1 (sl) 2019-05-31
CN106983735A (zh) 2017-07-28
CA3052460A1 (en) 2013-11-07
PE20190625A1 (es) 2019-04-26
PT3278792T (pt) 2019-05-23
RS57431B1 (sr) 2018-09-28
SI2844222T1 (sl) 2020-02-28
HUE037702T2 (hu) 2018-09-28
CU24304B1 (es) 2018-01-10
EP2659881A1 (en) 2013-11-06
GEP201706759B (en) 2017-10-25
JOP20200148A1 (ar) 2022-10-30
AU2017210571A1 (en) 2017-08-24
JOP20200147A1 (ar) 2022-10-30
EP3278792A1 (en) 2018-02-07
LT2659881T (lt) 2018-02-12
ES2673931T3 (es) 2018-06-26
PH12014502340B1 (en) 2014-12-22
DK2844220T3 (en) 2019-04-08
GEP201706736B (en) 2017-09-25
PT3189830T (pt) 2018-10-19
US10272048B2 (en) 2019-04-30
BR112014026933B1 (pt) 2022-07-19
LT2844222T (lt) 2019-12-27
KR20200073296A (ko) 2020-06-23
RS58625B1 (sr) 2019-05-31
ES2714448T3 (es) 2019-05-28
AU2013255914A1 (en) 2014-11-13
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
PT2844222T (pt) 2019-12-30
CR20190245A (es) 2019-07-29
KR20190127984A (ko) 2019-11-13
SG11201406798WA (en) 2014-11-27
US20150125525A1 (en) 2015-05-07
US10226430B2 (en) 2019-03-12
AU2017210571B2 (en) 2018-11-29
TR201905226T4 (tr) 2019-05-21
US20200214987A1 (en) 2020-07-09
JOP20200146A1 (ar) 2022-10-30
KR20200075024A (ko) 2020-06-25
PE20142442A1 (es) 2015-01-28
CA3080035A1 (en) 2013-11-07
RS59697B1 (sr) 2020-01-31
PT2844220T (pt) 2019-03-27
WO2013164315A1 (en) 2013-11-07
CU20140123A7 (es) 2015-02-26
EP3189830B1 (en) 2018-05-23
KR102104070B1 (ko) 2020-04-24
KR20150004910A (ko) 2015-01-13
PL2659881T3 (pl) 2018-05-30
CO7141433A2 (es) 2014-12-12
CY1121609T1 (el) 2020-05-29
KR102102198B1 (ko) 2020-04-21
AU2013255913A1 (en) 2014-11-13
CY1122475T1 (el) 2021-01-27
EP3187171A1 (en) 2017-07-05
EA201491781A1 (ru) 2014-12-30
DK2844222T3 (da) 2019-12-09
MX367127B (es) 2019-08-06
TW201343202A (zh) 2013-11-01
CN104302274A (zh) 2015-01-21
JOP20200148B1 (ar) 2023-09-17
CR20140486A (es) 2015-01-19
GEP201706758B (en) 2017-10-25
JOP20200145B1 (ar) 2023-09-17
ME03364B (me) 2019-10-20
US9814681B2 (en) 2017-11-14
CN104271113B (zh) 2019-03-22
TR201809416T4 (tr) 2018-07-23
PL3189830T3 (pl) 2018-11-30
MY169161A (en) 2019-02-19
US11534406B2 (en) 2022-12-27
CA3052460C (en) 2022-06-07
CA2871017A1 (en) 2013-11-07
CA2871016A1 (en) 2013-11-07
CO7151506A2 (es) 2014-12-29
EA032811B1 (ru) 2019-07-31
SG11201406799XA (en) 2014-11-27
CY1120492T1 (el) 2019-07-10
MX2014012887A (es) 2015-05-08
GEP201706753B (en) 2017-10-25
AU2017210577B2 (en) 2018-11-29
JOP20200144A1 (ar) 2017-06-16
US20170035698A1 (en) 2017-02-09
PT2659881T (pt) 2018-01-29
TWI705833B (zh) 2020-10-01
SI3278792T1 (sl) 2019-06-28
BR112014026933A2 (pt) 2017-06-27
CA2871016C (en) 2023-03-21
DK3189830T3 (en) 2018-07-16
TN2014000442A1 (en) 2016-03-30
JO3574B1 (ar) 2020-07-05
EP2844220B1 (en) 2019-01-23
RS58735B1 (sr) 2019-06-28
EP3189830A1 (en) 2017-07-12
SA115370043B1 (ar) 2016-05-24
JP2015515965A (ja) 2015-06-04
HUE042833T2 (hu) 2019-07-29
CN110200949A (zh) 2019-09-06
HUE036187T2 (hu) 2018-06-28
TN2014000441A1 (en) 2016-03-30
US20150132380A1 (en) 2015-05-14
BR122019022551B1 (pt) 2022-07-19
AR090898A1 (es) 2014-12-17
AU2013255914B2 (en) 2017-08-31
HRP20180965T1 (hr) 2018-08-10
JP6621662B2 (ja) 2019-12-18

Similar Documents

Publication Publication Date Title
SI3189830T1 (sl) Formulacija zdravila z zakasnjenim sproščanjem
JP6397813B2 (ja) ヒドロキシプロピルメチルセルロースアセテートスクシネート（ｈｐｍｃａｓ）の水性分散液
JP2016535030A5 (sl)
EP1221947A2 (en) Soft gel capsule resistant to gastric juices
EP2985020B1 (en) Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
AR103981A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención
CA2986188A1 (en) Pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
HRP20190727T1 (hr) Formulacija odgođenog otpuštanja lijeka
EP1663173A1 (en) Enteric soft gelatin capsule containing esomeprazole and method of preparation
AU2012334035A1 (en) Lubricious coatings
TW201329171A (zh) 潤滑塗層